PSA-based screening has always been one of the controversial topics among urological researchers.
In spite of its benefit in detecting early prostate cancer, PSA-based screening may not only result in widespread overdiagnosis and overtreatment of an often indolent disease, which is life-threatening in only a minority of patients, but also subject participators to such complications as erectile dysfunction and incontinence. Besides, whether PSA-based screening can reduce prostate cancer specific mortality has received considerable attention. This review offers a comparative analysis of recent studies on PSA-based screening for prostate cancer.
Written by:
Cao WL, Sun FK. Are you the author?
Department of Urology, Ruijin Hospital Affliated to Shanghai Jiaotong University, Shanghai 200025, China.
Reference: Zhonghua Nan Ke Xue. 2013 Jun;19(6):559-62.
PubMed Abstract
PMID: 23862239
Article in Chinese.
UroToday.com Prostate Cancer Section
